AI
ALXN

Atom Investors’s Alexion Pharmaceuticals ALXN Stock Holding History

Atom Investors’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-21,169
Closed -$3.24M – 371
2021
Q1 		$3.24M Buy
21,169
+10,294
+95% +$1.59M 0.54% 40
2020
Q4 		$1.7M Buy
10,875
+6,275
+136% +$806K 0.17% 146
2020
Q3 		$526K Buy
+4,600
New +$496K 0.05% 249
2019
Q4 		– Sell
-19,487
Closed -$1.91M – 343
2019
Q3 		$1.91M Buy
19,487
+5,112
+36% +$576K 0.13% 158
2019
Q2 		$1.88M Buy
+14,375
New +$1.85M 0.12% 192

Other funds holding ALXN

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return
DKCM
Davidson Kempner Capital Management New York $7.33B AUM 56.47% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return

Atom Investors's ALXN Position: Q2 2021 in Review

Atom Investors sold out of Alexion Pharmaceuticals (ALXN) in Q2 2021, closing a stake of 21,169 shares — an estimated $3.24M sold.

Atom Investors first reported a position in ALXN in Q2 2019 and held it in 5 quarters. The position peaked at $3.24M in Q1 2021. 707 funds tracked by Wall St. Rank hold ALXN as of Q2 2021.

  • Atom Investors reported no remaining Alexion Pharmaceuticals position as of Q2 2021 after selling out during the quarter.
  • Atom Investors sold 21,169 Alexion Pharmaceuticals shares in Q2 2021, an estimated $3.24M.
  • Atom Investors first reported a position in Alexion Pharmaceuticals in Q2 2019 and held it in 5 quarters.
  • Atom Investors's Alexion Pharmaceuticals position peaked at $3.24M in Q1 2021.
  • 707 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q2 2021.

Based on Atom Investors's 13F filing for Q2 2021, filed 16 Aug 2021.